USRE30910E - Reducing cholesterol levels - Google Patents

Reducing cholesterol levels Download PDF

Info

Publication number
USRE30910E
USRE30910E US06/117,239 US11723980A USRE30910E US RE30910 E USRE30910 E US RE30910E US 11723980 A US11723980 A US 11723980A US RE30910 E USRE30910 E US RE30910E
Authority
US
United States
Prior art keywords
compound
cholesterol
human
dihydroxy
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US06/117,239
Inventor
Alan H. Weigand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHOLEX LABORATORIES INC A CORP OF NY
Novartis Corp
Original Assignee
Intellectual Property Development Corp Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US346751A external-priority patent/US3859437A/en
Application filed by Intellectual Property Development Corp Pty Ltd filed Critical Intellectual Property Development Corp Pty Ltd
Application granted granted Critical
Publication of USRE30910E publication Critical patent/USRE30910E/en
Assigned to CHOLEX LABORATORIES, INC.; A CORP OF NY. reassignment CHOLEX LABORATORIES, INC.; A CORP OF NY. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: INTELLECTUAL PROPERTY DEVELOPMENT CORPORATION
Assigned to CIBA-GEIGY CORPORATION reassignment CIBA-GEIGY CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: CIBA-GEIGY CORPORATION
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Definitions

  • This invention relates to and has as its objective a method of reducing the levels of cholesterol and other lipids, especially triglycerides, in mammals.
  • Current medical theory holds that there is a causal relationship between elevated cholesterol and lipid levels and the development of artherosclerosis and other adverse conditions in mammals.
  • Artherosclerotic conditions are a major cause of death by virtue of their relation to hardening and narrowing of blood vessel walls and the occurrence of thromboses leading to coronary attacks and strokes.
  • the rate limiting step in the synthesis of cholesterol in the body may be the conversion of 3 ⁇ -hydroxy-3 ⁇ -methyl glutaric acid to mevalonic acid.
  • This reaction seems to be controlled by the activity of a catalytic enzyme, 3 ⁇ -hydroxy 3 ⁇ -methyl glutaryl CoA reductase. Therefore, by controlling the activity of this enzyme, the synthesis of cholesterol is controlled.
  • the synthesis of cholesterol in the body it is possible to reverse the mechanism whereby the body distributes and causes the deposit of excess cholesterol in various body pools, such as the gall bladder and blood vessels. Inhibiting or suppressing synthesis cholesterol, causes the body to deplete or withdraw from the various body pools, wherein excess cholesterol was previously deposited, the excess cholesterol therein deposited.
  • the suppression of cholesterol synthesis will result in the overall reduction of cholesterol and other lipid levels in the body.
  • the suppression of the synthesis of cholesterol will result in a reversal of the mechanism by which excess cholesterol was previously deposited in the various body pools and therefore will result in a lowering of the cholesterol and lipid levels in mammals.
  • a method to reduce the cholesterol and lipid, including triglyceride, levels of mammals which comprises administering to said mammals an effective amount of a composition selected from the group consisting of those of the formula: ##STR2## wherein R is selected from the group consisting of OH, NHCH 2 COOH and NHCH 2 CH 2 SO 3 H; each X is hydrogen; each Y is selected from the group consisting of hydroxy and acyloxy; and when taken together, X and Y is oxo (O ⁇ ).
  • the compounds of this invention may be administered in the form of their non-toxic pharmaceutically acceptable salts, for example, the alkaline metal salts, such as the sodium or potassium salts thereof.
  • administration of the compounds of Formula I of this invention to hypercholesteremic mammals results in the inhibition of activity of the rate limiting enzyme which controls the rate of cholesterol synthesis in mammals, and thus results in a lowering of the cholesterol and other lipid levels of the hypercholesteremic mammal being treated.
  • the inhibition of cholesterol synthesis by the practice of this invention results in a decrease of the natural distribution of cholesterol into the plasma and bile of the mammal being treated, and consequently will lead to a reversal of the process whereby excessive cholesterol has been previously deposited resulting in the formation of cholesterol gall stones and artherosclerotic plaque.
  • administration of the compounds of Formula I, in the practice of this invention, to hypercholesteremic mammals will apparently lead to a depletion of excessive cholesterol deposits in the body of said mammal, for example, cholesterol gall stones and artherosclerotic plaque.
  • the preferred acyloxy radicals are those of hydrocarbon carboxylic acids of less than twelve carbon atoms, as exemplified by the lower alkanoic acids (e.g., acetic, propionic, and butyric acids), the lower alkenoic acids, the monocyclic aryl carboxylic acids (e.g., benzoic and toluic acids), the monocyclic aryl lower alkanoic acids (e.g., phenacetic and-B-phenylpropionic acids), the cycloalkane carboxylic acids and the cycloalkene carboxylic acids.
  • the lower alkanoic acids e.g., acetic, propionic, and butyric acids
  • the lower alkenoic acids e.g., benzoic and toluic acids
  • the monocyclic aryl lower alkanoic acids e.g., phenacetic and-B-phenylpropionic acids
  • the cycloalkane carboxylic acids
  • compositions of this invention may be administered to the patients being treated in accordance with the method of this invention. It has been found that satisfactory results are obtained when the compositions of this invention are orally administered to the patient in a daily amount of from about 50 milligrams to about 1.5 grams. Best results appear to be obtained when the initial dosage is in the range of from about 0.5-1.5 gm. per day and then gradually reduced and maintained at a level of about 100 mg. per day depending upon the patient being treated and the results obtained.
  • the active substances of Formula I hereof may be incorporated in such suitable final dosage forms as may be satisfactorily prepared and employed by the worker skilled in the art.
  • the commonly employed, pharmaceutically acceptable dosage forms suitable for oral administration containing the active substance of Formula I in sufficient concentration to attain the desired results may be utilized.
  • the pharmaceutically acceptable, non-toxic inert carriers usually employed for such purposes may be utilized to prepare such dosage forms as tablets, capsules, elixirs, solutions, suspensions and the like. Most preferably, satisfactory results have been obtained by the use of tablets or capsules containing the active ingredient in a concentration of from about 50 to 500 mg., although other concentrations have also provided satisfactory results.
  • the invention may be further illustrated by the following Examples.
  • Final orally administerable dosage forms incorporating the amounts of active substances set forth in Table A were prepared and administered on a daily basis to patients having abnormally elevated lipid, for example cholesterol and triglyceride, levels. These materials were administered to the patients over an extended period of time during which there was a substantial reduction in the lipid, i.e., cholesterol and triglyceride, levels of the patients, to within normal ranges.
  • lipid for example cholesterol and triglyceride
  • Bile acids i.e., sodium taurocholate, sodium taurochenodeoxycholate and sodium taurodeoxycholate, were added to the stock diets at a level of 1%.
  • the experimental diets were fed for one week after which the bile ducts of the test animals were cannulated and their bile collected for a period of 30 to 60 minutes. At the end of the bile collection period, the test animals were sacrificed, their livers removed and a microsomal fraction was prepared by ultracentrifugation.
  • TCDC chenodeoxycholic acid
  • 3 ⁇ ,7 ⁇ -dihydroxy-5 ⁇ -cholanic acid was orally administered to the patient.
  • the daily dosage level of 3 ⁇ ,7 ⁇ -dihydroxy-5 ⁇ -cholanic acid was 750 mg., administered three times per day in capsule form, each containing 250 mg. of the compound.
  • the lipid values of the patient were found to be:
  • Two patients with elevated cholesterol level and cholelithiasis were treated with a compound of the instant invention to determine its effect in lowering the cholesterol level of the patients.
  • the patient E. Y. experienced a 70% reduction in the size of the cholesterol stones in the gall bladder (confirmed by radiological studies), without a concommitant rise in the patient's overall cholesterol level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)

Abstract

A method for reducing the levels of cholesterol and other lipids in mammals, which comprises administering to said mammals an effective amount of a substance having the formula, ##STR1## wherein R is selected from the group consisting of OH, NHCH2 COOH and NHCH2 CH2 SO3 H; each X is hydrogen, each Y is hydroxy or acyloxy, and when taken together X and Y is oxo (O═); and the nontoxic pharmaceutically acceptable salts thereof.

Description

This application .Iadd.is a continuation of Ser. No. 867,322 filed Jan. 5, 1978 which .Iaddend.is a continuation-in-part application of my previously filed, pending application, Ser. No. 259062 filed June 2, 1972 now abandoned, which is a continuation-in-part application of previously filed application Ser. No. 126,296, filed Mar. 19, 1971 now abandoned.
This invention relates to and has as its objective a method of reducing the levels of cholesterol and other lipids, especially triglycerides, in mammals. Current medical theory holds that there is a causal relationship between elevated cholesterol and lipid levels and the development of artherosclerosis and other adverse conditions in mammals. Artherosclerotic conditions are a major cause of death by virtue of their relation to hardening and narrowing of blood vessel walls and the occurrence of thromboses leading to coronary attacks and strokes.
In addition, it is believed that in many hypercholesteremic conditions over active or excessive cholesterol synthesis may be responsible for the development of the condition. When, in certain cases, excess cholesterol is synthesized and/or otherwise introduced into the system, the body reacts by distributing the excess cholesterol to various body pools where it is deposited and accumulates. Among the body pools wherein this excess cholesterol may be distributed and deposited are included the gall bladder, wherein the deposits take the form of cholesterol stones, and the blood vessels wherein the deposits may be in the form of artheroscelerotic plaque. Thus, the presence of excess levels of cholesterol in the body, to which the body naturally reacts by distribution and deposition thereof to various body pools, results in such adverse conditions as cholesterol gall stones and artherosclerotic plaque.
Presently there are available medically approved substances which are prophyllactically administered to patients for the purpose of reducing cholesterol and lipid blood levels. Such products, for example clofibrate, (commercially available from Ayerst Laboratories under the tradename, "Atromid"), are known cholesterol inhibitors and must be chronically administered in substantial daily doses over extended, and as yet not fully determined periods of time, perhaps years, to achieve their purpose. To date there is no knowledge as to the possible toxic effect the chronic administration of these presently known cholesterol inhibiting agents will have on the patients being treated. In addition, it does not appear that any of the substances hereinbefore administered to lower cholesterol and lipid levels has resulted in the reversal of the mechanism by which excess cholesteremic concentrations are deposited in various body pools, thereby creating the adverse conditions hereinbefore described.
It now appears that the rate limiting step in the synthesis of cholesterol in the body may be the conversion of 3β-hydroxy-3β-methyl glutaric acid to mevalonic acid. This reaction seems to be controlled by the activity of a catalytic enzyme, 3β-hydroxy 3β-methyl glutaryl CoA reductase. Therefore, by controlling the activity of this enzyme, the synthesis of cholesterol is controlled. By controlling the synthesis of cholesterol in the body, it is possible to reverse the mechanism whereby the body distributes and causes the deposit of excess cholesterol in various body pools, such as the gall bladder and blood vessels. Inhibiting or suppressing synthesis cholesterol, causes the body to deplete or withdraw from the various body pools, wherein excess cholesterol was previously deposited, the excess cholesterol therein deposited. Therefore, the suppression of cholesterol synthesis will result in the overall reduction of cholesterol and other lipid levels in the body. In fact, the suppression of the synthesis of cholesterol will result in a reversal of the mechanism by which excess cholesterol was previously deposited in the various body pools and therefore will result in a lowering of the cholesterol and lipid levels in mammals. More particularly, by suppression of cholesterol synthesis with a concommitant reversal of the mechanism of excess cholesterol deposition in various body pools, there results a reversal of such conditions as cholesterol gall stones, i.e., reduction and/or dissolution of the stones, and artherosclerotic plaque formation in blood vessels.
There has now been discovered a method whereby the cholesterol and lipid levels in mammals may be satisfactorily and safely reduced. More particularly, I have discovered a method to reduce the cholesterol and lipid, including triglyceride, levels of mammals which comprises administering to said mammals an effective amount of a composition selected from the group consisting of those of the formula: ##STR2## wherein R is selected from the group consisting of OH, NHCH2 COOH and NHCH2 CH2 SO3 H; each X is hydrogen; each Y is selected from the group consisting of hydroxy and acyloxy; and when taken together, X and Y is oxo (O═).
In addition, the compounds of this invention may be administered in the form of their non-toxic pharmaceutically acceptable salts, for example, the alkaline metal salts, such as the sodium or potassium salts thereof.
More particularly, it has been found that administration of the compounds of Formula I of this invention to hypercholesteremic mammals results in the inhibition of activity of the rate limiting enzyme which controls the rate of cholesterol synthesis in mammals, and thus results in a lowering of the cholesterol and other lipid levels of the hypercholesteremic mammal being treated. In fact, the inhibition of cholesterol synthesis by the practice of this invention results in a decrease of the natural distribution of cholesterol into the plasma and bile of the mammal being treated, and consequently will lead to a reversal of the process whereby excessive cholesterol has been previously deposited resulting in the formation of cholesterol gall stones and artherosclerotic plaque. Thus, administration of the compounds of Formula I, in the practice of this invention, to hypercholesteremic mammals, will apparently lead to a depletion of excessive cholesterol deposits in the body of said mammal, for example, cholesterol gall stones and artherosclerotic plaque.
In addition to the foregoing, it is now known that substantial amounts of cholesterol synthesized by the liver are converted by the body to desireable bile acids. The rate at which this conversion takes place is controlled by another enzyme, cholesterol-7α-hydroxylase. It has now been discovered that while certain bile acids, notably cholic acid, i.e. 3α, 7α, 12α-trihydroxy-5β-cholanic acid and deoxycholic acid, i.e. 3α, 12α-dihydroxy-5β-cholanic acid, have an adverse effect on the activity of this enzyme, the compounds of this invention have no adverse effect, and in some instances have apparently had an elevating effect on the cholesterol 7α-hydroxylase enzyme. Thus, it has also been found that the compounds of this invention reduce cholesterol by not interfering with and in some instances augmenting the bodys natural process of converting undesired cholesterol into desired bile acids. In addition to the foregoing, reference may be had to my pending prior filed application Ser. No. 304,295, filed Nov. 13, 1972, wherein it is shown that the cholesterol 7α-hydroxylase enzyme which controls the conversion of synthesized cholesterol into bile acids, is not adversely affected by the compounds of this invention.
The preferred acyloxy radicals are those of hydrocarbon carboxylic acids of less than twelve carbon atoms, as exemplified by the lower alkanoic acids (e.g., acetic, propionic, and butyric acids), the lower alkenoic acids, the monocyclic aryl carboxylic acids (e.g., benzoic and toluic acids), the monocyclic aryl lower alkanoic acids (e.g., phenacetic and-B-phenylpropionic acids), the cycloalkane carboxylic acids and the cycloalkene carboxylic acids.
In this Specification and in the Claims appended hereto, whenever in the structural formulae set forth therein the linkage of atoms is represented by a curved line it is meant to denote that the connected moiety may be in the α- or β-position as the case may be.
In the practice of the instant invention the preferred embodiment thereof is where R is --OH. Thus, in its preferred embodiment, this invention contemplates the employment of such compounds as 3α,7α-dihydroxy-5β-cholanic acid; 3α,7α-diacyloxy-5β-cholanic acid; 3,7α-dioxo-5β-cholanic acid; 3α, 7β-dihydroxy 5β-cholanic acid; 3α,7β-diacyloxy-5β-cholanic acid, 3α-hydroxy-7β-acetoxy-5β-cholanic acid; 3α-hydroxy-7α-acyloxy-5β-cholanic acid, for example, 3α-hydroxy-7α-acetoxy-5β-cholanic acid, and other like compounds. These compounds are well known in the art or easily derived from known compounds by chemical processes well known to those skilled in the art. In the most preferred embodiment of this invention, 3α,7α-dihydroxy-5β-cholanic acid is the compound utilized for the most satisfactory results.
Further satisfactory embodiments of the instant invention involve those compounds of Formula I wherein R is --NHCH2 COOH or --NHCH2 CH2 SO3 H. These materials are obtained by the conjugation of the respective free acids of Formula I, (i.e. wherein R is --OH), with the respective amino acids, i.e. glycine or taurine, by standard reactions which are well known to the art.
The compositions of this invention may be administered to the patients being treated in accordance with the method of this invention. It has been found that satisfactory results are obtained when the compositions of this invention are orally administered to the patient in a daily amount of from about 50 milligrams to about 1.5 grams. Best results appear to be obtained when the initial dosage is in the range of from about 0.5-1.5 gm. per day and then gradually reduced and maintained at a level of about 100 mg. per day depending upon the patient being treated and the results obtained.
In the practice of this invention, it has been found that most satisfactory results are obtained when up to about 750 mg. per day are administered to the hypercholesteremic patient being treated, the optimum daily dosage appearing to be about 500 to 750 mg. per day, although other dosage levels have been found to give beneficial results also. It has been found that the daily administration of more than 1.5 grams of the respective active substance of this invention imparts no additional beneficial effect to the patient beyond that achieved with a lesser daily dosage level.
To achieve the purpose and objectives of this invention, the active substances of Formula I hereof may be incorporated in such suitable final dosage forms as may be satisfactorily prepared and employed by the worker skilled in the art. Thus, the commonly employed, pharmaceutically acceptable dosage forms suitable for oral administration containing the active substance of Formula I in sufficient concentration to attain the desired results may be utilized. The pharmaceutically acceptable, non-toxic inert carriers usually employed for such purposes may be utilized to prepare such dosage forms as tablets, capsules, elixirs, solutions, suspensions and the like. Most preferably, satisfactory results have been obtained by the use of tablets or capsules containing the active ingredient in a concentration of from about 50 to 500 mg., although other concentrations have also provided satisfactory results.
The invention may be further illustrated by the following Examples.
EXAMPLE I
Final orally administerable dosage forms incorporating the amounts of active substances set forth in Table A were prepared and administered on a daily basis to patients having abnormally elevated lipid, for example cholesterol and triglyceride, levels. These materials were administered to the patients over an extended period of time during which there was a substantial reduction in the lipid, i.e., cholesterol and triglyceride, levels of the patients, to within normal ranges.
              TABLE A                                                     
______________________________________                                    
Material             Amount                                               
______________________________________                                    
3α,7α-dihydroxy-5β-cholanic acid                         
                     250 mg.                                              
12-desoxy-cholytaurine                                                    
                     250 mg.                                              
3α,7α-diacetoxy-5β-cholanic acid                         
                     250 mg.                                              
12-desoxy-cholylglycine                                                   
                     250 mg.                                              
3,7-dioxy-5β-cholanic acid                                           
                     250 mg.                                              
3α,7β-dihydroxy-5β-cholanic acid                          
                     250 mg.                                              
______________________________________
EXAMPLE II
Male Wistar rats were kept in individual cages and received a stock diet of ground Purina rat chow plus 5% corn oil. Bile acids, i.e., sodium taurocholate, sodium taurochenodeoxycholate and sodium taurodeoxycholate, were added to the stock diets at a level of 1%. The experimental diets were fed for one week after which the bile ducts of the test animals were cannulated and their bile collected for a period of 30 to 60 minutes. At the end of the bile collection period, the test animals were sacrificed, their livers removed and a microsomal fraction was prepared by ultracentrifugation. Assays of HMG-CoA reductase and cholesterol 7α-hydroxylase were carried out in accordance with the procedures described in 13 J. Lipid Research 402-412 (1972) and 9 J. Lipid Research 328-333 (1968), respectively. Liver cholesterol concentrations were measured by GLC.
The following table shows the results obtained:
______________________________________                                    
                    Enzyme       Liver                                    
Test       No.      Activity**   Cholesterol***                           
Compound   Animals  HMG      C-7H  Concentration                          
______________________________________                                    
Stock Diet 6        93.9     9.11  2.45                                   
(SD)                                                                      
SD + 1% TCDC                                                              
           6        35.1     8.49  2.57                                   
SD + 1% TDC                                                               
           4        63.8     7.22  3.78                                   
SD + 1% TC 6        36.6     3.08  6.09                                   
______________________________________                                    
 *TCDC = taurochenodeoxycholic acid                                       
 TDC = taurodeoxycholic acid                                              
 TC = taurocholic acid                                                    
 **HMG = HMG CoA reductase                                                
 C7H = cholesterol 7hydroxylase                                           
 Activity is given in pmoles/mg protein/min                               
 ***mg/g (wet wt.)
That these tests show that chenodeoxycholic acid (TCDC) significantly lowers the synthesis rate of cholesterol in the test animals by control of the enzyme, HMG-CoA reductase, without adversely effecting the rate of conversion of cholesterol to bile acids or adversely effecting the concentration of cholesterol in the liver.
EXAMPLE III
M.T., a 53 year old male suffering from Type V hyperlipidemia, i.e. elevated triglyceride and cholesterol levels, was observed for an eight day control period during which control values of his lipid levels were determined. The average control lipid values were:
______________________________________                                    
Cholesterol:      250 ± 7 mg/100 ml                                    
Triglycerides:    2021 ± 326 mg/100 ml                                 
______________________________________
Over a period of ten days, 3α,7α-dihydroxy-5β-cholanic acid was orally administered to the patient. The daily dosage level of 3α,7α-dihydroxy-5β-cholanic acid was 750 mg., administered three times per day in capsule form, each containing 250 mg. of the compound. At the end of the ten day period the lipid values of the patient were found to be:
______________________________________                                    
Cholesterol:      190 ± 18 mg/100 ml                                   
Triglycerides:    1484 ± 308 mg/100 ml                                 
______________________________________
No adverse reactions were experienced by the patient during or after this test.
EXAMPLE IV
Patients with elevated cholesterol levels were tested to determine the effect of the compound, 3α,7α-dihydroxy-5β-cholanic acid in lowering the level of cholesterol. The patients were studied to determine their control cholesterol values and then were treated with the test compound which was orally administered. The results are reported in Table B below:
              TABLE B                                                     
______________________________________                                    
               Cholesterol Values                                         
               After                                                      
Patient                                                                   
      Dosage    Control  1 Mo. 3 Mo. 4 Mo. 6 Mo.                          
______________________________________                                    
N. C. 750 mg/day                                                          
                262      246   207   --    --                             
R. R. "         271      --    --    173   --                             
C. F. "         305      --    --    266   --                             
K. S. "         230      --    --    107   --                             
G. W. "         450      --    --    --    358                            
______________________________________
There were no adverse reactions experienced during or after these tests by any of the patients.
EXAMPLE V
Two patients with elevated cholesterol level and cholelithiasis were treated with a compound of the instant invention to determine its effect in lowering the cholesterol level of the patients.
The results are reported in Table C below:
              TABLE C                                                     
______________________________________                                    
                   Cholesterol Values                                     
                   After                                                  
Patient                                                                   
      Test Compound Control  3 Mo. 7 Mo. 12 Mo.                           
______________________________________                                    
E. Y. 3α,7α-dihydroxy-                                        
      5β-cholanic acid                                               
                    243      258   --    244                              
T. S. 3α,7α-dihydroxy-                                        
      5β-cholanic acid                                               
                    279      --    235   --                               
______________________________________
After 12 months of administration of the compound of this invention, the patient E. Y. experienced a 70% reduction in the size of the cholesterol stones in the gall bladder (confirmed by radiological studies), without a concommitant rise in the patient's overall cholesterol level.
After 7 months of administration of the compound of this invention, the patient T. S., experienced total and complete disappearance of the stones in the gallbladder (confirmed by radiological studies), with a concurrent reduction in cholesterol levels in excess of 15%.
These tests evidence that the compounds of this invention reduce the overall cholesterol levels in the body of the patient being treated.
The invention may be variously otherwise embodied within the scope of the appended claims.

Claims (11)

    What is claimed is: .[.1. The method of reducing lipid levels of human beings, which comprises;
  1. and the non-toxic, pharmaceutically acceptable salts thereof..]. .[.2. The method of claim 1, wherein the compound is 3α,7α-dihydroxy-5β-cholanic acid..]. .[.3. The method of claim 1, wherein in the compound is administered in a daily dosage amount of about 750 mg. per day..]. .[.4. The method of claim 1, wherein in the
  2. compound each Y is hydroxy..]. .[.5. The method of claim 1, wherein the compound is 3α,7β-dihydroxy-5β-cholanic acid..]. .[.6. The method of reducing the cholesterol levels of human beings, which comprises;
    a. orally administering over an extended period of time, to a human being in a hypercholesteremic state;
    b. a small but effective amount sufficient to effect a reduction in the cholesterol level of said human being, of a compound of the formula: ##STR4## wherein
    R is OH, NHCH2 COOH, or NHCH2 CH2 SO3 H;
    each X is hydrogen;
    each Y is hydroxy or acyloxy; and X and Y when taken together is oxo (O═);
  3. and the non-toxic, pharmaceutically acceptable salts thereof..]. .[.7. The method of claim 6, wherein the compound is 3α,7α-dihydroxy-5β-cholanic acid..]. .[.8. The method of claim 6 wherein the compound is administered in a daily dosage amount of 750 mg. per day..]. .[.9. The method of claim 5, wherein the hypercholesteremic state of the human being is hypercholesterolemia..].
  4. .[.0. The method of claim 6, wherein the compound, each Y is hydroxy..]. .[.11. The method of claim 6, wherein the compound is 3α,7β-dihydroxy-5β-cholanic acid..]. .[.12. The method of reducing the triglyceride levels of human beings, which comprises;
    a. orally administering over an extended period of time, to a human being in a hypertriglyceridemic state;
    b. a small but effective amount sufficient to effect a reduction of the triglyceride level of said human being, of a compound of the formula: ##STR5## wherein R is OH, NHCH2 COOH, or NHCH2 CH2 SO3 H;
    each X is hydrogen;
    each Y is hydroxy, or acyloxy, and
    X and Y when taken together is oxo (O═); and the non-toxic,
  5. pharmaceutically acceptable salts thereof..]. .[.13. The method of claim 12, wherein the compound is 3α,7α-dihydroxy-5β-cholanic
  6. acid..]. .[.14. The method of claim 12, wherein the compound is administered in a daily dosage amount of about 750 mg. per day..]. .[.15. The method of claim 12, wherein in the compound, each Y is hydroxy..]. .[.16. The method of claim 12, wherein the compound is
  7. 3α,7β-dihydroxy-5β-cholanic acid..]. 17. The method of reducing cholesterol levels of human beings, which comprises;
    a. Orally administering over an extended period of time, to a human being suffering from cholelithiasis;
    b. A small but effective amount sufficient to effect a reduction in the cholesterol level of said human being, of a compound of the formula: ##STR6## wherein R is OH, NHCH2 COOH or NHCH2 CH2 SO3 H; each X is hydrogen;
    each Y is hydroxy or acyloxy; and
    X and Y when taken together is oxo (O═); and the non-toxic
  8. pharmaceutically acceptable salts thereof. .[.18. The method of claim 17, wherein the compound is 3α,7α-dihydroxy-5β-cholanic acid..]. .[.19. The method of claim 17, wherein the compound is
  9. 3α,7β-dihydroxy-5β-cholanic acid..]. .Iadd.20. The method of claim 17 wherein the compound is administered in a daily dosage amout
  10. of from about 0.5 to 1.5 grams per day. .Iaddend. .Iadd.21. The method of reducing cholesterol levels of human beings, which comprises:
    a. Orally administering over an extended period of time, to a human being suffering from cholelithiasis;
    b. A small but effective amount sufficient to effect a reduction in the cholesterol level of said human being, of the compound 3α,7β-dihydroxy-5β-cholanic acid, and the non-toxic
  11. pharmaceutically acceptable salts thereof. .Iaddend. .Iadd.22. The method of claim 21 wherein the compound is administered in a daily dosage amount of about 750 milligrams per day. .Iaddend. .Iadd.23. The method of claim 17 wherein the compound is administered in a daily dosage amount of about 500 to 750 milligrams per day. .Iaddend. .Iadd.24. The method of claim 17 wherein the compound is administered in a daily dosage amount of about 750 milligrams per day. .Iaddend. .Iadd.25. The method of claim 21 wherein the compound is administered in a daily dosage amount of from about 0.5 to 1.5 grams per day. .Iaddend. .Iadd.26. The method of claim 21 wherein the compound is administered in a daily dosage amount of about 500 to 750 milligrams per day. .Iaddend.
US06/117,239 1971-03-19 1980-01-31 Reducing cholesterol levels Expired - Lifetime USRE30910E (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12629671A 1971-03-19 1971-03-19
US25906272A 1972-06-02 1972-06-02
US346751A US3859437A (en) 1972-06-02 1973-04-02 Reducing cholesterol levels
US86732278A 1978-01-05 1978-01-05

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US346751A Reissue US3859437A (en) 1971-03-19 1973-04-02 Reducing cholesterol levels
US86732278A Continuation 1971-03-19 1978-01-05

Publications (1)

Publication Number Publication Date
USRE30910E true USRE30910E (en) 1982-04-20

Family

ID=27494640

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/117,239 Expired - Lifetime USRE30910E (en) 1971-03-19 1980-01-31 Reducing cholesterol levels

Country Status (1)

Country Link
US (1) USRE30910E (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921710A (en) 1988-07-21 1990-05-01 Iowa State University Research Foundation, Inc. Method of converting cholesterol in food to coprostanol
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5352682A (en) * 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5578304A (en) * 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
US20070078115A1 (en) * 1998-11-26 2007-04-05 Burdick David C Phytosterol and/or phytostanol derivatives

Non-Patent Citations (51)

* Cited by examiner, † Cited by third party
Title
Admirand et al., "The Physiochemical Basis of Cholesterol Gallstone Formation in Man", J. Clin. Invest. 47, 1043-1052, (1968).
Angelin et al., (Abstract) 6th Int'l. Symposium on Drugs Affecting Lipid Metabolism (1977).
Bateson et al., (Abstract) Ibid.
Bateson et al., British Medical Journal, May 6, 1978, pp. 1171-1173.
Bateson, Lancet, Oct. 30, 1976, pp. 962-963.
Bell et al., British Medical Journal 3: 520-522.
Bell et al., Surg. Gynecol. Obstet. 132 (1971), pp. 36-42.
Bell et al., The Lancet II (1972), pp. 1213-1216.
Bonorris et al., (abstract) Gastroenterology 67: 780 (1974).
Cole et al., J. Amer. Med. Assoc. 164, pp. 238-243, May 1957.
Comess et al., "New England J. Med.", (1967), 277, pp. 894-898.
Dam, American J. Med. 51 (1971), pp. 596-613.
Danzinger et al., "Gastroenterology", vol. 60, No. 1, p. 192.
Danzinger et al., "Gastroenterology", vol. 62, No. 1, p. 178.
Danzinger et al., "Gut", (1972), vol. 13, p. 321.
Danzinger et al., J. Clin. Inv. (1971), 50 p. 24(a).
Danzinger et al., New England Jour. Med. (1972), pp. 1-8.
Friedman et al., "J. Chronic Dis.", 19: (1966), pp. 273-292.
Gardener et al., "Quart. J. Med.", (1930), pp. 465-483.
Grundy et al., J. Clin. Investigation 45, (1966), pp. 1018-1019.
Grundy, Gastroenterology (1972), vol. 63, No. 1, pp. 201-203.
Hoffman et al., "Mayo Clin. Proc.", (1974), 49, pp. 236-239.
Hoffmann, "Alcohol and the Liver", (Int. Symp. at Frieburg, Notes Publ. (1971), pp. 421-433.
Hofmann et al., Hospital Practice, Aug. 1974, pp. 45 et seq.
Hofmann, Functions and Dysfunctions of Bile Acids published in Program of 14th Int. Con.-of Lipids, (Sweden) (1970).
Hofmann, Gut, 16: 1-17.
Isaacson, Acta Soc. Med. Upsal., (1954), vol. 59, p. 277.
Isselbacker, The New England Journal of Medicine 286, No. 1, pp. 40-42.
Johnson et al., A.M.A. Archives of Surgery, vol. 75 (1957), pp. 436-442.
Johnston et al., Arch. Surg. (1957), 75, pp. 436-442.
Marmo et al., (Abstract) Ibid.
Miller et al., Lancet, Oct. 19, 1974, pp. 929-931.
Modern Drug Encyclopedia (1949), p. 123.
Physicians' Desk Reference (1969), pp. 559-560.
Physician's Drug Reference (1971), p. 830.
Rewbridge, A. G., Surgery 1: (1937), pp. 395-400.
Salen et al., (abstract) Clinical Research 20: 465 (1973).
Salen et al., (abstract) Clinical Research 21: 523 (1973).
Salen et al., Gastroenterology 69: 676-684 (1975).
Shefer et al., "J. Lipid Research", 16 (1969), pp. 646-655.
Small, D. M., "Current Concepts, Gallstones", New Eng. J. of Med., 279, 588-593 (1968).
Small, New Engl. J. Med. 284 (1971), pp. 214-216.
Swell et al., Amer. J. Digest Dis. 13 (1968), pp. 1077-1080.
Thistle et al., "Gastroenterology", (1970), vol. 58, p. 1000.
Thistle et al., "Induced Alteration of Bile Composition in Humans with Cholelithiasis", J. Lab. Clin. Med. (1969), pp. 1020-1021.
Thistle et al., "Induced Alteration of Bile Composition in Humans with Cholelithiasis", J. Lab. Clin. Med. 42, 113 (Dec. 1969).
Thistle et al., "JAMA", (1978), 239, pp. 1041-1046.
Thistle et al., New England J. Med. (1971), pp. 177-180.
Todd-Sanford, Clinical Diagnosis by Laboratory Methods, 14th ed. (1959), 559-570.
Vlahcevic et al., "Gastroenterology", 56 (1969), p. 1204.
Vlahcevic et al., Gastroenterology, 59 (1970), pp. 165-173.

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
US4921710A (en) 1988-07-21 1990-05-01 Iowa State University Research Foundation, Inc. Method of converting cholesterol in food to coprostanol
US5405621A (en) * 1992-06-19 1995-04-11 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5324514A (en) * 1992-06-22 1994-06-28 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5578304A (en) * 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5234697A (en) * 1992-06-22 1993-08-10 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5352682A (en) * 1993-03-08 1994-10-04 Digestive Care Inc. Compositions containing salts of bile acid-aminosalicylate conjugates
US5674488A (en) * 1994-10-07 1997-10-07 Reich; John J. Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US20070078115A1 (en) * 1998-11-26 2007-04-05 Burdick David C Phytosterol and/or phytostanol derivatives

Similar Documents

Publication Publication Date Title
US3859437A (en) Reducing cholesterol levels
USRE30910E (en) Reducing cholesterol levels
US7012069B2 (en) Liver X receptor agonists
Baranowski et al. Connective tissue responses to oxysterols
US4396615A (en) Method of treating androgen-related disorders
Phillips et al. Inhibition of cholesterol biosynthesis in the rat by 3 β-(2-diethylaminoethoxy) androst-5-en-17-one, hydrochloride
AU756739B2 (en) Testosterone derivative
US4117121A (en) Method of increasing bile flow and decreasing lipid levels
US3852440A (en) Reducing cholesterol levels with sitosterols and cholanic acid derivatives
Vermeulen et al. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women
DE2759171A1 (en) MEDICINAL PRODUCTS WITH EFFECT AS PROSTAGLANDIN SYNTHETASE INHIBITOR
BG100098A (en) CRYSTAL SPIROSTANIL GLYCOSIDE MONOHYDRATE
EP0010056A1 (en) Corticoid sulfopropionic acid esters and their salts, process for their preparation and pharmaceutical preparations containing these compounds
EP0676203A1 (en) Pharmaceutical compositions of antiglucocorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal
US3931403A (en) Antimicrobial compositions
US3856953A (en) Method of treating fatty liver
US4079133A (en) Safer method for dissolving gallstones combining hyodeoxycholic acid with chenodeoxycholic acids
DE3339295C2 (en)
EP0155934B1 (en) Pharmaceutical compositions for treating androgen-related disorders in humans
EP1682156B1 (en) Strontium-based complexes, pharmaceutical compositions and dietetic products
Swell et al. Current concepts of the pathogenesis of cholesterol gallstones
US6326396B1 (en) Glucose and lipid lowering compounds
US3969503A (en) Compositions and methods useful in rendering lithogenic mammalian bile non-lithogenic
Khachadurian et al. Pravastatin decreases serum lipids and vascular cholesterol deposition in Watanabe heritable hyperlipidemic (WHHL) rabbits
Mosbach et al. Early pathologic and biochemical changes in rabbits fed dihydrocholesterol

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHOLEX LABORATORIES, INC.; A CORP OF NY.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:INTELLECTUAL PROPERTY DEVELOPMENT CORPORATION;REEL/FRAME:004113/0452

Effective date: 19821220

AS Assignment

Owner name: CIBA-GEIGY CORPORATION, 444 SAW MILL RIVER ROAD, A

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CIBA-GEIGY CORPORATION;REEL/FRAME:004552/0957

Effective date: 19860430

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: DEURSIL (URSODEOXYCHOLIC ACID); REQUESTED FOR 2 YEARS

Filing date: 19880216

Expiry date: 19920107

PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: DEURSIL (URSODEOXYCHOLIC ACID)

Filing date: 19880216

Expiry date: 19920107